Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity

Bone Marrow Transplantation volume 51, pages 319–321 (2016)Cite this article

Subjects

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard of care for patients with relapsed aggressive non-Hodgkin’s lymphoma (NHL).1, 2 Although the role of ASCT as part of first line treatment remains controversial for patients with diffuse large-B-cell lymphoma (DLBCL), high-dose chemotherapy followed by ASCT has been shown to be superior to standard chemotherapy in poor-risk patients with aggressive lymphoma according to the age-adjusted international prognostic index.3, 4, 5 Otherwise, ASCT can also be considered as an attractive treatment option for mantle-cell lymphoma (MCL) patients under 60 years.6, 7

Since the 1980’s, various conditioning regimens have been used and none of them has demonstrated superiority to another. To date, BEAM (carmustine 300 mg/m2 IV on day −6, etoposide 100 mg/m2 IV bid on day −5 to −2, cytarabine 100 mg/m2 IV bid on day −5 to −2, melphalan 140 mg/m2 on day −1)-conditioning regimen is one of the standards of care for first line or relapsed NHL patients receiving consolidation with ASCT.8, 9 Carmustine, one of the components of BEAM, is currently unavailable in France, due to a lack of production. In this situation, we had to make an institutional decision about an alternative conditioning regimen to use in lymphoid neoplasms such as NHL.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose chemotherapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987; 316: 1493–1498.

    Article  CAS  Google Scholar 

  2. Hagberg H, Gisselbrecht C, CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17 Suppl 4: iv31–iv32.

    Article  CAS  Google Scholar 

  3. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.

    Article  CAS  Google Scholar 

  4. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. N Engl J Med 2004; 350: 1287–1295.

    Article  CAS  Google Scholar 

  5. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol, a Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 2000; 18: 3025–3030.

    Article  CAS  Google Scholar 

  6. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, López-Guillermo A, Gisselbrecht C et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800.

    Article  Google Scholar 

  7. Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol 2014; 93: 233–242.

    Article  CAS  Google Scholar 

  8. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH . BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13: 588–595.

    Article  CAS  Google Scholar 

  9. Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.

    Article  CAS  Google Scholar 

  10. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.

    Article  CAS  Google Scholar 

  11. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–1210.

    Article  CAS  Google Scholar 

  12. Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood 2014; 124: 3029–3031.

    Article  CAS  Google Scholar 

  13. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood 2014; 124: 2306–2312.

    Article  CAS  Google Scholar 

  14. Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 831–837.

    Article  CAS  Google Scholar 

  15. Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007; 18: 587–595.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center Institut J. Paoli—I. Calmettes—Université de la Méditerranée, Marseille, France

    S Garciaz, D Coso, J-M Schiano de Collela, F Broussais, A-M Stoppa, T Aurran, C Chabannon, A Helvig, L Xerri, D Blaise & R Bouabdallah

Authors
  1. S Garciaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Coso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-M Schiano de Collela
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Broussais
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A-M Stoppa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Aurran
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Helvig
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Xerri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Bouabdallah.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garciaz, S., Coso, D., Schiano de Collela, JM. et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant 51, 319–321 (2016). https://doi.org/10.1038/bmt.2015.257

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.257

This article is cited by

Search

Advanced search

Quick links